Document Review Jobs in Princeton, NJ
Please select the country where you want to search for a job.
-
Job Type
-
Posting Date
6 Jobs Found | Sort By : Relevance | Posted Date
Less results matching your search!
Try removing some of the filters to get more results
No results matching your search!
Try removing some of the filters to get more results
Senior Cmc Project Manager (biologics)
Summit Therapeutics Sub
Princeton - USA
Location: Princeton NJ or Oxford UK (on-site)About Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single m...
Senior Cmc Project Manager (biologics)
Summit Therapeutics Sub
Princeton - USA
Location: Princeton NJ (on-site)About Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivon...
Associate Director, Cmcquality Project Management ...
Summit Therapeutics Sub
Princeton - USA
About Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays unique cooperat...
Director, Medical Affairs
Summit Therapeutics Sub
Princeton - USA
About Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigationalbispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays unique cooperati...
Director, Global Medical Affairs
Summit Therapeutics Sub
Princeton - USA
About Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigationalbispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays unique cooperati...
Medical Director
Summit Therapeutics Sub
Princeton - USA
About Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays unique cooperat...
